Arkitekt Ventures Research
Investment Thesis
Arkitekt Ventures is an early-stage healthcare venture capital firm founded by Dr. Enke Bashllari, a neuroscientist turned venture investor. The fund is dedicated to improving and advancing human health by partnering with visionary technical founders working on "the hard problems" at the intersection of science and technology. Arkitekt deliberately spans both service-heavy care delivery companies and deep frontier technology applications to medicine, reflecting a distinctive thesis that the future of care sits at the intersection of physical clinics and bleeding-edge technology.
The firm has an unusually high concentration in brain and nervous-system related innovation, suggesting a distinctive neuro + AI + delivery wedge inside healthtech. This positions Arkitekt at the forefront of solving complex healthcare challenges through scientific rigor and technological innovation.
Investment Strategy & Philosophy
Technology Focus Areas: Arkitekt invests in frontier technology applications including:
- Neurotech and brain-machine interfaces
- Artificial intelligence and machine learning for healthcare
- Augmented reality and virtual reality medical applications
- Quantum computing applications to medicine
- Novel AI-driven biology platforms and biotech
- Healthcare delivery innovation and novel care models
Founder Preference: The fund specifically backs technical founders—primarily scientists, engineers, and researchers transitioning from academia or research backgrounds into entrepreneurship. Enke Bashllari's background as a neuroscientist gives her deep credibility with this founder profile.
Contrarian Position: Arkitekt positions itself as a specialist in deep science and frontier technology where most traditional VCs lack expertise. By focusing on neurotech, AI-driven biology, and AR/VR applications to medicine—areas many generalist VCs avoid—the fund identifies contrarian opportunities in underexplored healthcare verticals before they become mainstream investment categories.
Investment Sectors & Technology Focus
Primary Sectors:
- Healthcare Digital (innovative care delivery, digital health platforms)
- Biotech & Life Sciences (AI-driven drug discovery, novel therapeutics)
- Neurotech (brain-machine interfaces, neural monitoring, cognitive enhancement)
- AI/ML Applications to Medicine (diagnostic AI, predictive healthcare)
- AR/VR Medical Applications (surgical visualization, medical training)
- Clinical Trials and Research Infrastructure
Technology Enablers:
- Artificial Intelligence and Machine Learning
- Brain-Computer Interfaces and Neural Technology
- AR/VR and Spatial Computing for Healthcare
- Biotech and Advanced Biology
Stage Focus & Check Size
Investment Stages:
- Primary: Seed stage ($1M-$5M typical)
- Secondary: Series A stage (follow-ons and selective new investments)
- Tertiary: Pre-Seed stage (selective)
Check Size Range:
- Pre-Seed: $0.5M-$1M
- Seed: $2M-$5M (typical)
- Series A: $7M-$12M (follow-on and selective new investments)
Geographic Focus
Primary: United States (New York headquartered, strong East Coast biotech connections)
Secondary: International (selective investments in Europe and beyond)
Recent Activity & Fund Status
Fund Status: Actively deploying
Recent Investments (2024-2025):
- Olli Health (November 2025) - Series A, $10M. Home health AI platform.
- Handspring Health (June 2025) - Series A, $12M. Digital therapeutics in fertility.
- Cofertility (April 2025) - Series A, $7.25M. Fertility and family planning.
- Sollis Health (December 2024) - Series B, $33M (participated). Healthcare delivery.
- Standard Model Biomedicine (October 2025) - Biotech in drug development.
Portfolio Companies (21+ investments documented):
- Paradromics - Brain-machine interface technology (led $7M seed, 2018)
- Mural Health - Clinical trial infrastructure
- CertifyOS - Healthcare credentialing and compliance
- Tia - Digital health platform
- Nanite - Healthcare analytics
- Parsley Health - Functional medicine
- NOVOS - Longevity and aging research
- HumanFirst (acquired by ICON, 2024) - Clinical trial logistics
Team & Leadership
Enke Bashllari, Ph.D. - Founder and Managing Director
- Background: Neuroscientist by training, transitioned to venture investing
- Education: Harvard Business School (MBA), Vagelos College of Physicians and Surgeons
- Recognition: Named one of Business Insider's "Top 40 Women in Early-Stage Venture Capital" (2025)
- Expertise: Neurotech, biotech, AI-driven healthcare, clinical innovation
- Founded Arkitekt in 2017 with mission to advance human health through frontier technology
The firm operates as a founder-led team with direct founder relationships and hands-on support.
Decision Process & Timeline
Decision Structure: Solo GP model with direct decision-making authority from Enke Bashllari
Due Diligence Approach:
- Heavy technical diligence leveraging neuroscience background
- Deep science validation and market assessment
- Founder-founder mentorship model
Timeline: Estimated 2-4 weeks for early-stage decision
Summary
Arkitekt Ventures represents a uniquely positioned early-stage healthcare venture fund led by a world-class technical investor (Enke Bashllari, Ph.D.). The firm's combination of deep scientific credibility, focus on frontier technology applications to healthcare, hands-on founder support, and contrarian thesis (backing "hard problems" others avoid) makes them ideally suited to identify and support the next generation of healthcare innovation leaders. Their investments in neurotech, AI-driven biology, digital therapeutics, and clinical innovation demonstrate commitment to solving fundamental healthcare challenges. The fund's ability to attract co-investment from tier-1 VCs validates their thesis and deal quality.